CDK19 Antibody

What is CDK19 and what is its biological significance?

CDK19 is a cyclin-dependent kinase that plays crucial roles in transcriptional regulation as part of the mediator complex. The protein is approximately 56.8 kilodaltons in mass and may also be known by alternative names including Cdc2L6, CDK11, bA346C16.3, CDC2-related protein kinase 6, and CDK8-like cyclin-dependent kinase . Recent research has identified CDK19 as a potential biomarker in cancer, with significant upregulation observed in hepatocellular carcinoma tissues compared to normal liver tissues . CDK19 appears to be directly involved in cell division and regulation of the G2/M cell cycle transition, suggesting its importance in cellular proliferation mechanisms . Investigations have further revealed that CDK19 is positively correlated with the abundances of CD4+ T cells, macrophages, and dendritic cells, indicating potential roles in immune regulation within the tumor microenvironment . Understanding CDK19's function is essential for interpreting experimental results when using CDK19 antibodies in research contexts.

What types of CDK19 antibodies are currently available for research applications?

Multiple types of CDK19 antibodies are available for research purposes, targeting different epitopes and offering various technical specifications. Polyclonal antibodies targeting specific regions (such as middle or C-terminal regions) provide broad epitope recognition and are often used for applications requiring high sensitivity . Monoclonal antibodies (such as clone 4E8) offer higher specificity for particular epitopes and may provide more consistent results across experiments . Researchers can select from antibodies with different reactivity profiles depending on their model system, with options available for human, mouse, rat, bovine, and canine samples . Both conjugated antibodies (with biotin, FITC, HRP, Alexa Fluor 750, Cy7, etc.) and unconjugated antibodies are commercially available, providing flexibility for different detection methods . The selection of an appropriate antibody should be based on the specific application, species reactivity requirements, and detection method planned for the experiment.

What are the validated applications for CDK19 antibodies in research?

CDK19 antibodies have been validated for several research applications, with distinct optimization requirements for each method. Western blotting (WB) represents one of the most common applications, allowing for protein expression quantification and confirmation of molecular weight (~56.8 kDa for CDK19) . Enzyme-linked immunosorbent assay (ELISA) provides a quantitative approach for detecting CDK19 in solution, though this requires carefully validated antibody pairs . Immunohistochemistry (IHC) enables tissue localization and expression pattern analysis, requiring optimization of fixation and antigen retrieval protocols . Immunofluorescence (IF) is valuable for studying subcellular localization and potential co-localization with other proteins, particularly useful in investigating CDK19's role in the mediator complex and other cellular components . Each application requires specific optimization steps, including antibody concentration determination, buffer composition adjustment, and appropriate control selection to ensure reliable and reproducible results.

How should I validate the specificity of a CDK19 antibody for my research?

Rigorous validation of CDK19 antibody specificity is critical for generating reliable research data and should involve multiple complementary approaches. Begin with Western blot analysis to confirm that the antibody recognizes a protein of the expected molecular weight (approximately 56.8 kDa for CDK19), looking for a single clean band without non-specific binding . Including positive control samples (tissues or cell lines known to express CDK19) and negative controls (tissues with minimal CDK19 expression) provides essential reference points for evaluating antibody performance . Consider implementing knockdown experiments using shRNA technology targeting CDK19, as described in hepatic cell line experiments, to confirm that the signal diminishes correspondingly with reduced CDK19 expression . For comprehensive validation, compare results using multiple antibodies targeting different CDK19 epitopes to ensure consistent detection patterns across different recognition sites. Additional validation could include immunoprecipitation followed by mass spectrometry identification of the pulled-down protein, providing definitive confirmation of antibody specificity beyond traditional methods.

What methodological considerations are important for studying CDK19 expression in cancer tissues?

When investigating CDK19 expression in cancer tissues, several methodological considerations must be addressed to ensure meaningful results. Sample preparation represents a critical initial step, with appropriate fixation methods essential for preserving CDK19 epitopes while maintaining tissue architecture for accurate localization assessment . Optimize antigen retrieval protocols specifically for CDK19 detection, as this protein may require particular pH conditions or retrieval methods for optimal epitope exposure . Always include both cancerous and adjacent normal tissue samples for direct comparison, as the search results indicate significant differences in CDK19 expression between HCC tissues and normal liver tissues . Consider the heterogeneity of cancer tissues by analyzing multiple areas within each sample and including sufficient biological replicates to account for patient-to-patient variability. Quantification methods should be standardized, whether using digital image analysis for immunohistochemistry or normalization protocols for Western blotting, to allow for reliable comparison between samples . Additionally, correlate CDK19 expression with clinical data and molecular features (such as TP53 mutation status) to identify potentially meaningful associations, as research has shown CDK19 expression correlates with sex, tumor stage, and TP53 mutation status in HCC .

What techniques can be used to investigate CDK19's role in the cell cycle and transcriptional regulation?

Investigating CDK19's role in cell cycle regulation and transcriptional processes requires sophisticated methodological approaches that extend beyond basic antibody applications. Chromatin immunoprecipitation sequencing (ChIP-seq) using validated CDK19 antibodies can map genomic binding sites, revealing the specific DNA regions where CDK19-containing mediator complexes associate with the genome during transcriptional regulation . Cell synchronization experiments followed by time-course analysis of CDK19 expression, phosphorylation status, and subcellular localization using specific antibodies can reveal how CDK19 function changes throughout the cell cycle phases . Co-immunoprecipitation studies with CDK19 antibodies followed by mass spectrometry can identify cell cycle-related and transcriptional regulation binding partners, providing insights into the protein interaction network . Proximity ligation assays combining CDK19 antibodies with antibodies against other regulatory proteins allow visualization of protein-protein interactions in situ, preserving cellular context that may be lost in extraction-based methods. Functional studies using CDK19 knockdown or overexpression systems can be coupled with cell cycle analysis, transcriptome profiling, and phenotypic assays to determine the functional consequences of CDK19 activity modulation on cell proliferation and gene expression patterns .

What are common technical issues when using CDK19 antibodies and how can they be addressed?

Researchers frequently encounter technical challenges when working with CDK19 antibodies that can be systematically addressed through methodological refinements. Non-specific binding representing one of the most common issues can be mitigated by optimizing blocking conditions (using appropriate blocking agents such as BSA or normal serum) and carefully titrating antibody concentrations to find the optimal signal-to-noise ratio . Inconsistent results between experiments might stem from lot-to-lot variability in antibody production, which can be addressed by purchasing larger lots when possible and maintaining detailed records of antibody performance across different batches . Weak or absent signals may result from ineffective epitope exposure, particularly in fixed tissues, requiring optimization of antigen retrieval methods (heat-induced or enzymatic) specific to the CDK19 epitope being targeted . Cross-reactivity with related proteins (such as CDK8 or other CDK family members) can confound interpretation and may necessitate using antibodies targeting unique regions of CDK19 or validating results with orthogonal methods . Inappropriate storage or handling of antibodies can lead to degradation and reduced performance, emphasizing the importance of following manufacturer recommendations regarding temperature, freeze-thaw cycles, and addition of preservatives .

How do I reconcile conflicting results from different CDK19 antibodies?

Conflicting results from different CDK19 antibodies represent a challenging but not uncommon scenario in research that requires systematic investigation. Begin by examining the epitope targets of each antibody, as antibodies recognizing different regions of CDK19 (middle region versus C-terminal region) may yield different results if post-translational modifications, protein interactions, or conformational changes differentially affect epitope accessibility . Compare the specifications of each antibody, including whether they are monoclonal (recognizing a single epitope) or polyclonal (recognizing multiple epitopes), as this fundamental difference can impact detection patterns, particularly in applications like immunohistochemistry . Validate each antibody's specificity using knockdown or knockout approaches to definitively determine which antibody most accurately reflects true CDK19 expression . Consider that results might not actually be conflicting but rather revealing different aspects of CDK19 biology, such as different isoforms, phosphorylation states, or protein complexes . Implement orthogonal methods that don't rely on antibodies, such as mRNA analysis or mass spectrometry, to provide independent confirmation of CDK19 expression or modification status . Consulting literature and contacting antibody manufacturers can provide insights into known limitations or specific recommended applications for each antibody that might explain discrepancies.

How can CDK19 antibodies be used to investigate the relationship between CDK19 and TP53 mutations in cancer?

The significant correlation between CDK19 expression and TP53 mutation status in hepatocellular carcinoma (p = 0.00012) suggests a biologically important relationship that warrants detailed investigation . Researchers can employ multiplexed immunohistochemistry or immunofluorescence using validated antibodies against both CDK19 and TP53 (wild-type and common mutant forms) to examine their co-expression patterns and potential co-localization within the same cellular compartments across patient samples . Co-immunoprecipitation experiments using CDK19 antibodies followed by Western blotting for TP53 (or vice versa) can reveal whether these proteins physically interact, directly or as part of larger complexes, potentially providing mechanistic insights into their functional relationship . Chromatin immunoprecipitation sequencing (ChIP-seq) with CDK19 antibodies in TP53 wild-type versus mutant cell lines can identify differential genomic binding patterns that might explain transcriptional dysregulation in the context of TP53 mutations . Functional studies involving CDK19 knockdown or overexpression in TP53 mutant versus wild-type backgrounds, followed by phenotypic assays examining proliferation, migration, invasion, and apoptosis, can elucidate whether CDK19 represents a synthetic lethal target in TP53-mutated cancers . Integration of these experimental approaches with patient data analysis can potentially identify patient subgroups that might benefit from therapeutic strategies targeting CDK19, particularly in the context of TP53 mutations.

What approaches can reveal CDK19's interaction with the immune microenvironment in cancer?

The positive correlation between CDK19 expression and the abundance of CD4+ T cells, macrophages, and dendritic cells revealed in the search results suggests important immunological functions that can be investigated through multiple approaches . Multiplex immunohistochemistry or immunofluorescence combining CDK19 antibodies with markers for specific immune cell populations (CD4 for T cells, CD68 for macrophages, CD11c for dendritic cells) enables spatial analysis of CDK19-expressing cells relative to immune infiltrates, potentially revealing patterns of interaction within the tumor microenvironment . Single-cell RNA sequencing coupled with protein analysis using CDK19 antibodies can precisely identify which cell types express CDK19 within the heterogeneous tumor microenvironment and characterize their transcriptional states and potential signaling pathways . In vitro co-culture systems combining CDK19-expressing cancer cells with various immune cell populations, followed by functional assays examining immune cell activation, cytokine production, and cytotoxicity, can provide mechanistic insights into how CDK19 influences immune responses . Examination of CDK19 expression in response to immune-modulating agents (such as cytokines or checkpoint inhibitors) might reveal regulatory mechanisms linking CDK19 to immune activation or suppression pathways . Animal models with genetic manipulation of CDK19 can be used to study changes in tumor immune infiltration in vivo, potentially providing translational insights relevant to immunotherapy approaches.

How can researchers investigate the potential of CDK19 as a therapeutic target in cancer?

Investigating CDK19 as a potential therapeutic target requires comprehensive approaches spanning from basic mechanism studies to translational applications. Researchers should begin with detailed expression profiling using validated CDK19 antibodies across diverse cancer types and patient subgroups to identify malignancies with significant CDK19 upregulation, building upon the evidence of CDK19 overexpression in hepatocellular carcinoma . Genetic manipulation studies using CRISPR-Cas9 knockout, shRNA knockdown, or overexpression systems can establish whether cancer cells exhibit dependency on CDK19 for survival, proliferation, migration, or other malignant properties, as suggested by the functional characterization experiments mentioned in the search results . Structure-function analyses employing domain-specific antibodies and mutation approaches can identify critical regions of CDK19 that might be targeted by small molecule inhibitors or other therapeutic modalities . Screening of compound libraries against purified CDK19 protein or CDK19-expressing cell lines can identify potential inhibitors, which can then be validated using CDK19 antibodies to confirm target engagement through techniques such as cellular thermal shift assays or drug affinity responsive target stability approaches. Biomarker development utilizing CDK19 antibodies for immunohistochemistry or circulating tumor DNA analysis might enable patient stratification for future clinical trials targeting CDK19, particularly considering the prognostic significance of CDK19 expression in certain HCC patient subgroups .

What are the expression patterns of CDK19 across different cancer types and normal tissues?

The available research data indicates distinct expression patterns of CDK19 across tissue types, with particularly notable upregulation in hepatocellular carcinoma compared to normal liver tissue . In HCC specifically, CDK19 shows differential expression patterns that correlate with several clinical and molecular features, including significantly higher expression in stage 3 versus stage 1 patients (p = 0.0021) and markedly elevated expression in patients with TP53 mutations compared to those without (p = 0.00012) . Analysis across different patient subgroups reveals variations in CDK19 expression related to sex, age, race, and weight, suggesting complex regulatory mechanisms influenced by both intrinsic and environmental factors . The table below summarizes key expression patterns documented in hepatocellular carcinoma:

While the search results focus primarily on hepatocellular carcinoma, researchers should conduct comprehensive expression profiling across additional cancer types and normal tissues to fully characterize CDK19's tissue-specific regulation and potential role in other malignancies .

What data exists regarding CDK19 mutations and their functional implications?

According to the search results, CDK19 mutations occur at a relatively low frequency of approximately 1% in hepatocellular carcinoma patients, as documented through comprehensive genomic analyses using databases such as cBioPortal and COSMIC . Current evidence suggests no significant relationship between CDK19 mutations and patient prognosis in HCC, indicating that CDK19 overexpression rather than mutation may be the more clinically relevant alteration . The functional consequences of CDK19 mutations remain largely unexplored, representing an important area for future research using techniques such as site-directed mutagenesis to introduce specific mutations identified in patients, followed by functional characterization . Protein structure analysis could provide insights into how mutations might affect CDK19's kinase activity, interaction with cyclins or other binding partners, or incorporation into the mediator complex . Computational approaches integrating mutation data with protein structure information and evolutionary conservation analysis could predict which mutations are likely to be functionally significant versus passenger alterations . A comprehensive table cataloging known CDK19 mutations, their frequencies across cancer types, and predicted functional impacts would be valuable for researchers but would require integration of data beyond what is provided in the current search results.

What is known about the protein-protein interaction network of CDK19?

The search results provide insights into CDK19's interaction network, particularly highlighting 10 hub genes strongly correlated with CDK19 in hepatocellular carcinoma, 8 of which demonstrated significant prognostic value . Protein-protein interaction (PPI) analyses indicate that CDK19 is involved in several critical cellular functions including proliferation, migration, and invasion, consistent with its roles in cell division and regulation of the G2/M cell cycle transition . As a component of the mediator coactivator complex, CDK19 interacts with transcriptional machinery to regulate gene expression, though specific binding partners within this complex are not detailed in the provided search results . The table below summarizes key aspects of CDK19's known interaction network:

Further research using techniques such as proximity ligation assays, co-immunoprecipitation followed by mass spectrometry, and BioID or APEX2 proximity labeling could provide more comprehensive mapping of CDK19's protein interaction network in different cellular contexts and disease states .

What are promising approaches for developing more specific and sensitive CDK19 antibodies?

Advancing CDK19 antibody technology requires innovative approaches to overcome current limitations in specificity and sensitivity. Researchers should consider employing recombinant antibody technologies, including phage display libraries and synthetic antibody platforms, to generate highly specific CDK19 binders targeting unique epitopes that distinguish CDK19 from closely related family members like CDK8 . Development of phospho-specific antibodies recognizing CDK19 at different phosphorylation states would significantly enhance our understanding of CDK19 activation mechanisms and signaling dynamics, providing crucial tools for studying its regulation . Single-domain antibodies (nanobodies) derived from camelid species offer advantages of smaller size and potentially better access to structurally hindered epitopes, which might be particularly valuable for studying CDK19 within protein complexes like the mediator . Antibody engineering approaches such as affinity maturation and stability optimization could enhance performance in challenging applications such as live-cell imaging or in vivo studies . Validation strategies for next-generation CDK19 antibodies should be increasingly rigorous, incorporating CRISPR knockout cell lines as gold-standard negative controls and quantitative binding affinity determinations using techniques like surface plasmon resonance . Cross-reactivity profiling against all related CDK family members should become standard practice to ensure specificity claims are substantiated before research application.

What methodological advances are needed to better understand CDK19's tissue-specific functions?

Advancing our understanding of CDK19's tissue-specific functions requires methodological innovations across multiple research domains. Development of conditional and tissue-specific CDK19 knockout or knockin mouse models would enable detailed in vivo analysis of CDK19's role in different tissues during development and disease progression, overcoming limitations of cell line studies . Three-dimensional organoid culture systems derived from different tissues (liver, colon, brain, etc.) combined with CRISPR-mediated CDK19 manipulation could provide physiologically relevant models for studying tissue-specific functions while maintaining the complexity of cellular interactions . Single-cell multi-omics approaches integrating transcriptomics, proteomics, and epigenomics at the individual cell level would reveal cell type-specific CDK19 expression patterns and regulatory networks within heterogeneous tissues, providing unprecedented resolution of its functional diversity . Development of highly selective CDK19 chemical probes (as distinct from therapeutic inhibitors) would enable acute perturbation studies to distinguish direct from adaptive effects of CDK19 inhibition in different tissue contexts . Spatial transcriptomics and proteomics technologies combined with CDK19 antibody-based detection could map expression patterns within tissue architecture, potentially revealing microenvironmental factors that influence CDK19 expression and function across different anatomical regions . These methodological advances would collectively provide a more comprehensive understanding of how CDK19 functions in a tissue-specific manner, potentially revealing new therapeutic opportunities.